SPOTLIGHT -
Fear, which gripped the United States just 50 days ago when terrorists launched attacks against the World Trade Center in New York City and at the Pentagon in Washington, DC, soon turned to resolve to help those who needed it most.
Aurion Biotech doses first Canadian patient in Phase 1/2 ABA-1, CLARA clinical trial of AURN001
EyePod: Modifier Gene Therapy: What is it?
Navigating ocular effects of cancer therapy: Insights from breast cancer and head-neck cancers
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
ABVC BioPharma reaches global licensing deal for ophthalmology pipeline
Plastic surgery: When specialties overlap